A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 30-40

  Wong, Y Nancy ^a,b   Simcoe, Donna ^a   Hartman, Linda N ^a   Laughton, Watson B ^a   King, S Peter ^a   McCormick, George C ^a   Grebow, Peter E ^a  

^a CEPHALON INC   (United States)

^b EISAI RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MODAFINIL; MODAFINIL ACID; MODAFINIL SULFONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENANTIOMER; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INSOMNIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL; TABLET; TACHYCARDIA; VOLUNTEER;

EID: 0032924254     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007534     Document Type: Article

References (23)

1. Czeisler CA, Richardson GS, Martin JB: Disorders of sleep and circadian rhythms. In, Lsselbacher K. J. et al (eds.): Harrison's Principles of Internal Medicine. 13th ed. New York: McGraw-Hill, 1994;162-171.
2. Report of the National Commission on Sleep Disorders Research: Wake Up America: A National Sleep Alert. January 1993.
3. Mignot E, Lin X, Arrigoni J, et al: DQB1'0602 and DQA1'0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994;17:S60-S67.
4. Parkes J: Amphetamines and alertness. In, Guilleminault C, Dement W, Passouant P (eds.): Narcolepsy. New York: Spectrum Publications, 1976;643-658.
5. Takahaski S: The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In, Guilleminault C, Dement W, Passouant P (eds.): Narcolepsy. New York: Spectrum Publications, 1976;303-310.
6. Hoffman BB, Lefkowitz RJ: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In, Molinoff PB, Ruddon RW (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: Macmillan, 1996;225-232.
7. Fuxe K, Rambert FA, Ferraro L, O'Connor W, Laurent PH, Agnati LF, Tanganelli S: Preclinical studies with modafinil: evidence for vigilance enhancement and neuroprotection. Drugs of Today 1996;32:313-326.
8. Lagarde DPS, Anton G: Comparative study of stimulant effects of d-amphetamine sulfate and modafinil, an original psychostimulant. Eur J Pharmacol 1990;183:1476.
9. Duteil J, Rambert FA, Pessonier J, Hermant J-F, Gombert R: Central alpha-adrenergic stimulation in relation to the behavior stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990;180:49-58.
10. Lin J, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immonochemistry in the cat. Neurobiology 1996;93:14128-14133.
11. Lyons TJ, French J: Modafinil: the unique properties of a new stimulant. Aviat Space Environ Med 1991;62:432-435.
12. Moachon G, Kanmacher I, Clenet M, Matinier D: Pharmacokinetic profile of modafinil. Drugs of Today 1996;32:327-337.
13. U.S. Modafinil in Narcolepsy Study Group: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
14. Gorman SH: A reverse-phase HPLC assay for the determination of d-and l-modafinil in human plasma. Pharm Res 1995;12:S-22.
15. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
16. PC SAS for Windows Version 6.08 (1994), SAS Institute, Cary, NC.
17. WinNonLin Standard Editions Version 1.0 (1995), Scientific Consulting, Inc., Apex, NC.
18. Kaiser G, Ackerman S, Brechbuhler, Dieterle W: Pharmacokinetics of the angiotensin converting enzyme inhibitor benzapril HCL (CGS 14824A) in healthy volunteers after single and repeated administration. Biopharm Drug Dispos 1989;10:365-376.
19. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE: Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998;38:276-282.
20. Drayer DE: Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther 1986;40:125-132.
21. Cotzias GC, Papavasiliou PS, Gellene R: Modification of Parkinsonism: chronic treatment with l-dopa. N Engl J Med 1969;280:337-345.
22. Satoh K, Yanagisawa T, Taira N: Coronary vasodilator and cardiac effects of optical isomers of verapamil in the dog. J Cardiovasc Pharmacol 1980;2:309-318.
23. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al: Randomized, double-blind, placebo-controlled cross-over trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.